1 reports of this reaction
3.3% of all CHELIDONIUM MAJUS reports
#14 most reported adverse reaction
RENAL FAILURE ACUTE is the #14 most commonly reported adverse reaction for CHELIDONIUM MAJUS, manufactured by BM Private Limited. There are 1 FDA adverse event reports linking CHELIDONIUM MAJUS to RENAL FAILURE ACUTE. This represents approximately 3.3% of all 30 adverse event reports for this drug.
Patients taking CHELIDONIUM MAJUS who experience renal failure acute should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RENAL FAILURE ACUTE is moderately reported among CHELIDONIUM MAJUS users, representing a notable but not dominant share of adverse events.
In addition to renal failure acute, the following adverse reactions have been reported for CHELIDONIUM MAJUS:
The following drugs have also been linked to renal failure acute in FDA adverse event reports:
RENAL FAILURE ACUTE has been reported as an adverse event in 1 FDA reports for CHELIDONIUM MAJUS. This does not prove causation, but indicates an association observed in post-market surveillance data.
RENAL FAILURE ACUTE accounts for approximately 3.3% of all adverse event reports for CHELIDONIUM MAJUS, making it a notable side effect.
If you experience renal failure acute while taking CHELIDONIUM MAJUS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.